Xiaofu Zhu

555 total citations
24 papers, 352 citations indexed

About

Xiaofu Zhu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Xiaofu Zhu has authored 24 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Xiaofu Zhu's work include HER2/EGFR in Cancer Research (4 papers), Cancer Treatment and Pharmacology (3 papers) and Cancer Diagnosis and Treatment (3 papers). Xiaofu Zhu is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Cancer Treatment and Pharmacology (3 papers) and Cancer Diagnosis and Treatment (3 papers). Xiaofu Zhu collaborates with scholars based in Canada, United States and France. Xiaofu Zhu's co-authors include Kelvin Chan, Georges Adunlin, Mark Vincent, George Dranitsaris, Kelly Lien, Gemma Cramarossa, Rebecca Wong, Ronak Saluja, Christina Korownyk and Ruth Dubin and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Cancer and European Journal of Cancer.

In The Last Decade

Xiaofu Zhu

22 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaofu Zhu Canada	8	121	117	97	92	36	24	352
Amanda Grattan Australia	5	106 0.9×	81 0.7×	49 0.5×	81 0.9×	34 0.9×	7	355
Rola Hamood Israel	9	161 1.3×	44 0.4×	63 0.6×	28 0.3×	48 1.3×	9	354
Hatem Hamood Israel	11	159 1.3×	63 0.5×	68 0.7×	17 0.2×	48 1.3×	11	343
Giovanni La Croce Italy	14	39 0.3×	145 1.2×	189 1.9×	49 0.5×	32 0.9×	50	515
P. Gerry Fegan Australia	13	50 0.4×	42 0.4×	104 1.1×	34 0.4×	34 0.9×	47	610
Chakkarin Burudpakdee United States	13	71 0.6×	92 0.8×	39 0.4×	54 0.6×	50 1.4×	42	487
Rebeka Tabbey United States	10	63 0.5×	87 0.7×	26 0.3×	23 0.3×	34 0.9×	15	372
Tracey K. Asano Canada	7	417 3.4×	82 0.7×	330 3.4×	63 0.7×	11 0.3×	8	652
Corina Bello Switzerland	11	30 0.2×	36 0.3×	86 0.9×	33 0.4×	31 0.9×	28	270
Joyce Wong China	9	76 0.6×	17 0.1×	119 1.2×	45 0.5×	35 1.0×	17	324

Countries citing papers authored by Xiaofu Zhu

Since Specialization

Citations

This map shows the geographic impact of Xiaofu Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaofu Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaofu Zhu more than expected).

Fields of papers citing papers by Xiaofu Zhu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaofu Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaofu Zhu. The network helps show where Xiaofu Zhu may publish in the future.

Co-authorship network of co-authors of Xiaofu Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaofu Zhu. A scholar is included among the top collaborators of Xiaofu Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaofu Zhu. Xiaofu Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Newell, Marnie, Gilbert Bigras, Susan Goruk, et al.. (2025). Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double‐blind, randomized controlled DHA‐WIN trial. International Journal of Cancer. 157(7). 1405–1419. 1 indexed citations

Cook, Sarah, Shabbir M.H. Alibhai, Caroline Mariano, et al.. (2024). Improving Care for Older Adults with Cancer in Canada: A Call to Action. Current Oncology. 31(7). 3783–3797. 1 indexed citations

Bessudo, Alberto, Abdul Haseeb, James A. Reeves, et al.. (2024). Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer. Clinical Colorectal Cancer. 23(3). 285–294. 4 indexed citations

Mei, Lina, et al.. (2023). Development and validation of a novel anoikis-related gene signature for predicting prognosis in ovarian cancer. Aging. 15(9). 3410–3426. 3 indexed citations

Abraham, Aswin, Diane Severin, Nawaid Usmani, et al.. (2023). 206 Sharing Mono-Institutional Experience of Treating Pancreatic Cancer with Stereotactic Body Radiation Therapy (SBRT) as an Adjuvant Therapy for Non-Operative Patients or Salvaging Local Failure. Radiotherapy and Oncology. 186. S90–S91.

Zhu, Xiaofu, Susan Dent, Lise Paquet, et al.. (2021). How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients. Current Oncology. 28(1). 800–812. 6 indexed citations

Clemons, Mark, Dean Fergusson, Anil A. Joy, et al.. (2021). A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. The Breast. 58. 42–49. 9 indexed citations

Kirkham, Amy A., Karen King, Anil A. Joy, et al.. (2021). Rationale and design of the Diet Restriction and Exercise-induced Adaptations in Metastatic breast cancer (DREAM) study: a 2-arm, parallel-group, phase II, randomized control trial of a short-term, calorie-restricted, and ketogenic diet plus exercise during intravenous chemotherapy versus usual care. BMC Cancer. 21(1). 1093–1093. 27 indexed citations

Okines, Alicia, Elisavet Paplomata, Tanya A. Wahl, et al.. (2020). Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).. Journal of Clinical Oncology. 38(15_suppl). 1043–1043. 5 indexed citations

10.

Clemons, Mark, Dean Fergusson, Anil A. Joy, et al.. (2020). A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer.. Journal of Clinical Oncology. 38(15_suppl). 7001–7001. 1 indexed citations

11.

Dranitsaris, George, Xiaofu Zhu, Georges Adunlin, & Mark Vincent. (2018). Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs. Expert Review of Pharmacoeconomics & Outcomes Research. 18(4). 351–357. 41 indexed citations

12.

Allan, G. Michael, Danielle Perry, Joey Ton, et al.. (2018). PubMed. 64(2). e64–e75.

13.

Clemons, Mark, Sasha Mazzarello, John Hilton, et al.. (2018). Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC). Supportive Care in Cancer. 27(4). 1345–1354. 4 indexed citations

14.

Dudani, Shaan, Xiaofu Zhu, Daniel Yokom, et al.. (2017). Radical Treatment of Stage II Non–small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes. Clinical Lung Cancer. 19(1). e11–e18. 4 indexed citations

15.

Zhu, Xiaofu & Anil A. Joy. (2017). Targeting HER2 in Advanced Breast Cancer. Methods in molecular biology. 1652. 63–77. 4 indexed citations

16.

Dudani, Shaan, Natasha B. Leighl, Cheryl Ho, et al.. (2016). Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists. Lung Cancer. 94. 74–80. 7 indexed citations

17.

Jacobs, Carmel, Eitan Amir, Alexander Paterson, Xiaofu Zhu, & Mark Clemons. (2015). Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting. Journal of bone oncology. 4(2). 54–58. 16 indexed citations

18.

Zhu, Xiaofu, Susan Dent, Lise Paquet, et al.. (2014). Factors influencing Oncotype DX use in the management of early breast cancer: A single centre experience. European Journal of Cancer. 50(15). 2544–2549. 4 indexed citations

19.

Zhu, Xiaofu, Eitan Amir, Gurmit Singh, Mark Clemons, & Christina Addison. (2014). Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting. Journal of bone oncology. 3(1). 1–4. 4 indexed citations

20.

Ko, Dennis T., Harindra C. Wijeysundera, Xiaofu Zhu, Janice A. Richards, & Jack V. Tu. (2008). Canadian quality indicators for percutaneous coronary interventions. Canadian Journal of Cardiology. 24(12). 899–903. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact